<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="45b366a9-6c0c-4643-9951-4ff880b29c83"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <effectiveTime value="20221220"/>
   <setId root="fcc7ac79-cd70-4f03-a4de-f051f9ca1f7d"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="055750020" root="1.3.6.1.4.1.519.1"/>
            <name>International Medication Systems, Limited </name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="055750020" root="1.3.6.1.4.1.519.1"/>
                        <name>International Medication Systems, Limited </name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="76329-3302" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="76329-3302" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="ebc8dd16-d821-4c08-88d7-c8a64a82558d"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL listing data elements section"/>
               <effectiveTime value="20211111"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="76329-3302" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>
                  Dextrose Monohydrate
                </name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Dextrose Monohydrate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="25" unit="g"/>
                              <denominator value="50" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="LX22YL083G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Dextrose monohydrate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5SL0G7R0OK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ANHYDROUS DEXTROSE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water </name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="50" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="76329-3302-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20211111"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20211111"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA203451" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <effectiveTime>
                              <low value="20210326"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="809a99a7-9302-4990-98fe-82374fa6014e"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>50% Dextrose Injection, USP</paragraph>
                  <paragraph>Concentrated Dextrose for Intravenous Administration<br/>
                     <content styleCode="bold">NOTE: This solution is hypertonic âˆ’ See Warnings and Precautions.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20221214"/>
            </section>
         </component>
         <component>
            <section>
               <id root="7776ddc0-28f0-4845-b6f6-4586f3b9ff93"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION </title>
               <text>
                  <paragraph>50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for injection for intravenous injection as a fluid and nutrient replenisher.<br/>Â Â Â  Each mL of fluid contains 0.5 g dextrose, hydrous which delivers 3.4 kcal/gram. The solution has an osmolarity of 2.5 mOsmol/mL (calc.) and a pH of 3.2-6.5. May contain Hydrochloric acid and/or Sodium hydroxide for pH adjustment.<br/>Â Â Â  The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only for use as a single-dose injection. When smaller doses are required, the unused portion should be discarded with the entire unit.<br/>Â Â Â  Dextrose, USP is chemically designated C<sub>6</sub>H<sub>12</sub>O<sub>6</sub> â€¢ H<sub>2</sub>O (D-glucose monohydrate), a hexose sugar freely soluble in water. Dextrose, hydrous has the following formula:</paragraph>
                  <paragraph>
                     <content>
                        <renderMultiMedia referencedObject="L97e4fcdf-9f70-405c-acce-0c4a592497f5"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content>Water for Injection, USP is chemically designated H</content>
                     <sub>2</sub>
                     <content>O.</content>
                  </paragraph>
                  <paragraph>The delivery device is composed of a 50 mL glass syringe barrel with rubber stopper, and custom molded IMS injector with Luer Connector.</paragraph>
               </text>
               <effectiveTime value="20221220"/>
               <component>
                  <observationMedia ID="L97e4fcdf-9f70-405c-acce-0c4a592497f5">
                     <text>structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="ec8392ad-284a-4bb1-bac0-e70f136f58e6"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY </title>
               <text>
                  <paragraph>
              When administered intravenously this solution restores blood glucose levels in hypoglycemia and provides a source of carbohydrate calories.<br/>Â Â Â  Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextrose injection undergoes oxidation to carbon dioxide and water.<br/>Â Â Â  Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).<br/>Â Â Â  Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na+) plays a major role in maintaining physiologic equilibrium.
            </paragraph>
               </text>
               <effectiveTime value="20210326"/>
            </section>
         </component>
         <component>
            <section>
               <id root="04b06910-e44c-40a8-b0db-65f19152ff27"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>
              50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels.<br/>Â Â Â  The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. Slow infusion of hypertonic solutions is essential to ensure proper utilization of dextrose and avoid production of hyperglycemia.
            </paragraph>
               </text>
               <effectiveTime value="20210326"/>
            </section>
         </component>
         <component>
            <section ID="CONTRAINDICATIONS ">
               <id root="33a71d8d-2e18-49fb-8aee-ef1ff55b84e2"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS </title>
               <text>
                  <paragraph>
              A concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present, nor in the presence of delirium tremens if the patient is already dehydrated.<br/>Dextrose injection without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.
            </paragraph>
               </text>
               <effectiveTime value="20210326"/>
            </section>
         </component>
         <component>
            <section ID="WARNINGS">
               <id root="e24d5fc5-8042-4ede-befc-34a546781dfc"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS </title>
               <text>
                  <paragraph>
              50% Dextrose Injection is hypertonic and may cause phlebitis and thrombosis at the site of injection.<br/>Â Â Â  Significant hyperglycemia and possible hyperosmolar syndrome may result from too rapid administration. The physician should be aware of the symptoms of hyperosmolar syndrome, such as mental confusion and loss of consciousness, especially in patients with chronic uremia and those with known carbohydrate intolerance.<br/>Â Â Â  The intravenous administration of this solution can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.<br/>Â Â Â  Additives may be incompatible. Consult with pharmacist if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.<br/>
                     <content styleCode="bold">Â Â Â  For peripheral vein administration:</content>
                     <br/>The solution should be given slowly, preferably through a small bore needle into a large vein, to minimize venous irritation.<br/>
                     <content styleCode="bold">Â Â Â  For central venous administration:</content>
                     <br/>Concentrated dextrose should be administered via central vein only after suitable dilution.
            </paragraph>
               </text>
               <effectiveTime value="20210326"/>
            </section>
         </component>
         <component>
            <section ID="PRECAUTIONS ">
               <id root="429e21f9-0e6c-4926-8bf3-519f05d60e4b"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS </title>
               <text>
                  <paragraph>Do not use unless the solution is clear and seal is intact. Discard unused portion.<br/>Â Â Â  Electrolyte deficits, particularly in serum potassium and phosphate, may occur during prolonged use of concentrated dextrose solutions. Blood electrolyte monitoring is essential and fluid and electrolyte imbalances should be corrected. Essential vitamins and minerals also should be provided as needed.<br/>Â Â Â  To minimize hyperglycemia and consequent glycosuria, it is desirable to monitor blood and urine glucose and if necessary, add insulin.<br/>Â Â Â  When a concentrated dextrose infusion is abruptly withdrawn, it is advisable to follow with the administration of 5% or 10% dextrose injection to avoid rebound hypoglycemia.<br/>Â Â Â  Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.<br/>Â Â Â  Care should be exercised to ensure that the needle is well within the lumen of the vein and that extravasation does not occur. If thrombosis should occur during administration, the injection should be stopped and corrective measures instituted.<br/>Â Â Â  Concentrated dextrose solutions should not be administered subcutaneously or intramuscularly.<br/>
                     <content styleCode="bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</content>
                     <br/>
                     <content styleCode="italics">Pregnancy Category C</content>. Animal reproduction studies have not been conducted with dextrose. It is also not known whether dextrose can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose should be given to a pregnant woman only if clearly needed.<br/>
                     <content styleCode="bold">Â Â Â  Nursing Mothers:</content>
                     <br/>Â Â Â  It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when 50% Dextrose Injection, USP is administered to a nursing mother.</paragraph>
               </text>
               <effectiveTime value="20210326"/>
            </section>
         </component>
         <component>
            <section>
               <id root="809789dc-8a18-486a-83a7-e26b27cbb5c6"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS </title>
               <text>
                  <paragraph>
              Hyperosmolar syndrome, resulting from excessively rapid administration of concentrated dextrose may cause mental confusion and/or loss of consciousness.<br/>Â Â Â  Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.<br/>Â Â Â  If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
            </paragraph>
               </text>
               <effectiveTime value="20210326"/>
            </section>
         </component>
         <component>
            <section>
               <id root="9c9fa28e-78fa-450b-b452-9e5e7d00efa9"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE </title>
               <text>
                  <paragraph>In the event of overhydration or solute overload during therapy, re-evalutate the patient and institute appropriate corrective measures. SeeÂ Â <linkHtml href="#WARNINGS">WARNINGS</linkHtml> and Â <linkHtml href="#PRECAUTIONS ">PRECAUTIONS</linkHtml>
                  </paragraph>
               </text>
               <effectiveTime value="20210326"/>
            </section>
         </component>
         <component>
            <section>
               <id root="e13b008c-d2b7-4775-9b71-50157d98cbf9"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">For peripheral vein administration: </content>
                     <br/>Â Â Â  Injection of the solution should be made <content styleCode="italics">slowly</content>. The maximum rate at which dextrose can be infused without producing glycosuria is 0.5 g/kg of body weight/hour. About 95% of the dextrose is retained when infused at a rate of 0.8 g/kg/hr. <br/>Â Â Â  In insulin-induced hypoglycemia, intravenous injection of 10 to 25 grams of dextrose (20 to 50 mL of 50% dextrose) is usually adequate. Repeated doses and supportive treatment may be required in severe cases. A specimen for blood glucose determination should be taken before injecting the dextrose. In such emergencies, dextrose should be administered promptly without awaiting pretreatment test results.</paragraph>
                  <paragraph>
                     <content styleCode="bold">For central vein administration: </content>
                     <br/>Â Â Â  For total parenteral nutrition 50% Dextrose Injection, USP is administered by slow intravenous infusion (a) after admixture with amino acid solutions via an indwelling catheter with the tip positioned in a large central vein, preferably the superior vena cava, or (b) after dilution with sterile water for injection. Dosage should be adjusted to meet individual patient requirements. <br/>Â Â Â  Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. <br/>Â Â Â  The maximum rate of dextrose administration which does not result in glycosuria is the same as cited above. <br/>Â Â Â  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. SeeÂ  <linkHtml href="#CONTRAINDICATIONS ">CONTRAINDICATIONS</linkHtml> .</paragraph>
               </text>
               <effectiveTime value="20210326"/>
            </section>
         </component>
         <component>
            <section>
               <id root="8f52cae6-d04e-4934-a213-15b9d0b1e90e"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED </title>
               <text>
                  <paragraph>50% Dextrose Injection, USP 25 g/50 mL (0.5 g/mL) is supplied in single-dose prefilled syringes as follows:</paragraph>
                  <paragraph>
                     <content styleCode="bold"> NDC No.Â Â Â Â Â Â Â Â Â Â  Stock No.Â Â Â Â Â Â Â Â Â Â  Container SizeÂ Â Â Â Â Â Â Â Â Â  Needle</content>
                  </paragraph>
                  <paragraph>76329-3302-1Â Â Â Â Â  Â  3302Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  50 mLÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â  None</paragraph>
                  <paragraph>One shrink wrapped package containing 10 unit cartons, each containing a Luer-Jetâ„¢ Luer-Lock Prefilled Syringe.</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Syringe Assembly Directions:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">USE ASEPTIC TECHNIQUE</content>
                     <br/>
                     <content styleCode="bold">Do not assemble until ready to use.</content>
                  </paragraph>
                  <paragraph>
                     <content>
                        <renderMultiMedia referencedObject="Lb717c459-9259-4e6d-be54-86c7f1a795b9"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content>*CAUTION: IMPROPER ENGAGING MAY CAUSE GLASS BREAKAGE AND SUBSEQUENT INJURY.</content>
                  </paragraph>
                  <paragraph>Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. Store at 20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]</paragraph>
                  <paragraph>
                     <br/>Revised 01/21</paragraph>
                  <paragraph>6933010E</paragraph>
                  <paragraph/>
                  <paragraph>Â© International Medication Systems, Ltd., 2021</paragraph>
                  <paragraph>International Medication Systems, Ltd.<br/>South El Monte, CA 91733, USA<br/>An Amphastar Pharmaceuticals Company<br/>Printed in USA</paragraph>
               </text>
               <effectiveTime value="20221214"/>
               <component>
                  <observationMedia ID="Lb717c459-9259-4e6d-be54-86c7f1a795b9">
                     <text>instructions</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="instructions.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="6f07eff7-d2d8-48d4-807c-5c6108ce9a36"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Carton </title>
               <text>
                  <paragraph>Principal Display Panel Text:</paragraph>
                  <paragraph>
                     <content styleCode="bold">open</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Luer-Lock Prefilled Syringe</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 76329-3302-1Â Â Â Â Â Â Â Â Â  STOCK NO. 3302</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>Â Â Â Â Â Â Â Â Â  One 50 mL Single-Dose Prefilled Syringe</paragraph>
                  <paragraph>
                     <content styleCode="bold">50% Dextrose Injection, USP</content>
                     <br/>
                     <content styleCode="bold">25 g/50 mL</content>
                     <br/>(0.5 g/mL)</paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR INTRAVENOUS USE</content>
                  </paragraph>
                  <paragraph>Single use, do not reuse or resterilize.</paragraph>
                  <paragraph>
                     <content styleCode="bold">LUER-JETâ„¢ LUER-LOCK PREFILLED SYRINGE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Ldbde0c5a-3af4-4957-a24b-7fa64566adae"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20221220"/>
               <component>
                  <observationMedia ID="Ldbde0c5a-3af4-4957-a24b-7fa64566adae">
                     <text>carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>